SEC Form 4 · accession 0001725092-26-000004

Cue Biopharma, Inc. · CUE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jun 1, 2026

Accepted (ET)

Jun 3, 2026 · 5:30 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001645460

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Pre-Funded Warrants (Right to Buy)^F2,F3,F1	$0.001	Jun 1, 2026	P	90,906	A	Jun 1, 2026	—	Common Stock	90,906	90,906	I
Common Stock Warrants (Right to Buy)^F2,F3	$11.00	Jun 1, 2026	P	45,453	A	Jun 1, 2026	May 4, 2031	Common Stock	45,453	45,453	I

F1The securities do not have an expiration date.
F2On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.
F3The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.